FDA Grants AP Status for Capecitabine ANDA210203 by Hetero Labs
Hetero Labs has received an Abbreviated Approval (AP) for their ANDA210203 application for Capecitabine.
Published: July 9, 2026
Updated: July 9, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy
Company: Hetero Labs
Asset: Capecitabine
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Hetero Labs
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's grant of Abbreviated Approval for Hetero Labs' generic Capecitabine introduces significant competition in the oncology market. This could impact pricing strategies and market share for both the generic and branded versions of the drug.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Hetero Labs and competitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.